Immunotope and Immunovaccine Announce U.S. Patent for Therapeutic Cancer Vaccine Antigens
Complete the form below to unlock access to ALL audio articles.
Immunotope Inc. and Immunovaccine Inc. have announced that the U.S. Patent and Trademark Office has issued an official Notice of Allowance for a new U.S. Patent specific to the DPX-0907 therapeutic cancer vaccine.
The new U.S. patent application titled "Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer" provides additional intellectual property protection in the U.S. for the seven antigens used in Immunovaccine's DPX-0907, a therapeutic cancer vaccine for patients with breast, ovarian or prostate cancers.
"We are delighted that the U.S. Patent and Trademark Office has recognized the novelty of our cancer antigens. The issuance of this patent will enhance the commercial potential of DPX-0907 in the largest market for cancer therapeutics in the world," commented Dr. Ramila Philip, President and CSO of Immunotope Inc.
"This new patent, in addition to our family of patents relating to our DepoVax™ vaccine delivery platform, provides a very strong intellectual property position for DPX-0907 in the U.S." said Dr. Marc Mansour, Vice President of R&D at Immunovaccine Inc.
In July 2009, Immunovaccine obtained exclusive worldwide rights to license the seven antigens from Immunotope. These antigens are believed to be present on the surface of breast, ovarian and prostate cancers and part of critical cancer cell processes. For more information on the seven antigens visit www.imvaccine.com/userfiles/file/7CancerAntigens.pdf
Immunovaccine is completing a Phase I clinical trial for DPX-0907 and preliminary results have shown the vaccine to be well tolerated and safe. Immunovaccine has recently completed enrollment for this trial and will be evaluating additional safety and immune response data that will be available in the second quarter of 2011.
